Mehla, Jogender http://orcid.org/0000-0003-0971-9620
Singh, Itender
Diwan, Deepti
Nelson, James W.
Lawrence, Molly
Lee, Eunjae
Bauer, Adam Q.
Holtzman, David M.
Zipfel, Gregory J.
Funding for this research was provided by:
NIH (NS103276, NS071011, NS090934, AG047644)
Knight ADRC (P50-AG05681)
Article History
Received: 30 August 2021
Accepted: 15 November 2021
First Online: 15 December 2021
Declarations
:
: Animal experimental procedures were approved by the Animals Studies Committee at Washington University in St. Louis and complied with the NIH Guide for the Care and Use of Laboratory Animals and with Washington University Department of Comparative Medicine guidelines. For human brain samples, all participants gave prospective premortem written consent for their brains to be banked and used for research.
: All authors consented to the publication of the manuscript.
: D.M.H. is as an inventor on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. C2N Diagnostics has licensed certain anti-tau antibodies to AbbVie for therapeutic development. D.M.H. is on the scientific advisory board of Denali and consults for Genentech, Merck, and Cajal Neuroscience. The remaining authors have declared that no conflict of interest exists.